These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11209988)

  • 1. Fibrinolytic factors and atherothrombotic events: epidemiological evidence.
    Folsom AR
    Ann Med; 2000 Dec; 32 Suppl 1():85-91. PubMed ID: 11209988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemostatic risk factors for cardiovascular diseases.
    Koenig W
    Eur Heart J; 1998 Apr; 19 Suppl C():C39-43. PubMed ID: 9597424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms].
    Banfi C; Mussoni L; Tremoli E
    Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis and the risk of venous and arterial thrombosis.
    Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T
    Curr Opin Hematol; 2007 May; 14(3):242-8. PubMed ID: 17414214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease.
    Vaughan DE
    Eur Heart J; 1998 Jul; 19 Suppl G():G9-12. PubMed ID: 9717049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fibrinolytic system in chronic renal failure.
    Lottermoser K; Petras S; Pöge U; Fimmers R; Hertfelder HJ; Schiermeyer B; Vetter H; Düsing R
    Eur J Med Res; 2001 Sep; 6(9):372-6. PubMed ID: 11591527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease.
    Agirbasli M
    Int J Clin Pract; 2005 Jan; 59(1):102-6. PubMed ID: 15707473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measures of thrombosis and fibrinolysis.
    Choi BG; Vilahur G; Ibanez B; Zafar MU; Rodriguez J; Badimon JJ
    Clin Lab Med; 2006 Sep; 26(3):655-78, vii. PubMed ID: 16938589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease.
    Gorog DA
    J Am Coll Cardiol; 2010 Jun; 55(24):2701-9. PubMed ID: 20538163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes mellitus as a prothrombotic condition.
    Grant PJ
    J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The risk indices for atherothrombotic disease: the coagulation factors].
    Coccheri S
    Ann Ital Med Int; 1991; 6(4):408-15. PubMed ID: 1804286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
    Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
    J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
    Pradhan AD; LaCroix AZ; Langer RD; Trevisan M; Lewis CE; Hsia JA; Oberman A; Kotchen JM; Ridker PM
    Circulation; 2004 Jul; 110(3):292-300. PubMed ID: 15238458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
    Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T
    Semin Thromb Hemost; 2009 Jul; 35(5):468-77. PubMed ID: 19739037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fibrinolytic system in children.
    Albisetti M
    Semin Thromb Hemost; 2003 Aug; 29(4):339-48. PubMed ID: 14517746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view.
    Folsom AR
    Thromb Haemost; 2001 Jul; 86(1):366-73. PubMed ID: 11487026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.
    Nordt TK; Peter K; Ruef J; Kübler W; Bode C
    Thromb Haemost; 1999 Sep; 82 Suppl 1():14-8. PubMed ID: 10695479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
    Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
    Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.
    Mavri A; Alessi MC; Juhan-Vague I
    J Intern Med; 2004 Apr; 255(4):448-56. PubMed ID: 15049879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.